What is the role of elotuzumab (Empliciti) in the treatment of relapsed multiple myeloma (MM)?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Elotuzumab (Empliciti) is a humanized IgG1 monoclonal antibody that specifically targets the SLAMF7 (signaling lymphocytic activation molecule family member 7) protein. SLAMF7 is expressed on myeloma cells and natural killer cells and plasma cells. Elotuzumab facilitates the interaction with natural killer cells to mediate the killing of myeloma cells through antibody-dependent cellular cytotoxicity. It is indicated for use in combination with lenalidomide and dexamethasone for MM in patients who have received 1-3 prior therapies.

Approval was based on the ELOQUENT-2 trial, a randomized, open-label clinical study that included 646 participants with multiple myeloma who had experienced relapse or who had not responded to previous treatment. The addition of elotuzumab to the combination of lenalidomide and dexamethasone extended PFS to 19.4 months, as compared with 14.9 months in patients treated with lenalidomide and dexamethasone (P< 0.001). Additionally, the overall response rate (including complete and partial responses) was 78.5%, compared with 60.1% in patients receiving lenalidomide and dexamethasone (P< 0.001). [94]

The ELOQUENT-3 trial studies 117 patients with MM that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor. Patients received elotuzumab plus pomalidomide and dexamethasone or pomalidomide and dexamethasone alone (control group). Median PFS was 10.3 months in the elotuzumab group and 4.7 months in the control group. The overall response rate was 53% in the elotuzumab group compared with 26% in the control group. [95]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!